/IMGN

IMGN Stock - ImmunoGen, Inc.

Q: What is the analyst price target for IMGN?

Analyst price target information is not currently available for IMGN.

Q: What is IMGN's market cap?

Market capitalization information is not currently available for IMGN.

Healthcare|Biotechnology|NASDAQ

$31.23+0.02%

+$0.01 (+0.02%) • Feb 9

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-59.3%upside

Target: $12.71

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for IMGN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.17

52W High$31.25

52W Low$3.61

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$108.78M	$69.86M	$132.30M	$82.27M	$53.82M
Gross Profit	$108.61M	$69.86M	$17.71M	$-32,251,000	$-120,070,000
Gross Margin	99.8%	100.0%	13.4%	-39.2%	-223.1%
Operating Income	$-220,893,000	$-125,073,000	$-135,485,000	$-92,173,000	$-160,479,000
Net Income	$-222,929,000	$-139,303,000	$-66,683,000	$-122,093,000	$-167,873,000
Net Margin	-204.9%	-199.4%	-50.4%	-148.4%	-311.9%
EPS	$-0.88	$-1.08	$-0.38	$-0.82	$-1.20

Company Overview

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Visit Website

Earnings History & Surprises

IMGN

Beat Rate

76%

Last 17 quarters

Avg Surprise

+32.8%

EPS vs Estimate

Beats / Misses

13/4

Last 12 quarters

Latest EPS

$-0.23

Q1 2024

EPS Surprise History

Q2 22

+52.4%

$-0.10vs$-0.21

Q3 22

-9.1%

$-0.24vs$-0.22

Q4 22

-19.2%

$-0.31vs$-0.26

Q1 23

+20.7%

$-0.23vs$-0.29

Q2 23

+36.0%

$-0.16vs$-0.25

Q3 23

+87.5%

$-0.02vs$-0.16

Q4 23

+124.1%

$0.10vs$0.04

Q1 24

-276.9%

$-0.23vs$0.13

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2024	Oct 31, 2024	—	—	—	—
Q3 2024	Jul 29, 2024	—	—	—	—
Q2 2024	Apr 26, 2024	—	—	—	—
Q1 2024	Mar 6, 2024	$0.13	$-0.23	-276.9%	✗ MISS
Q4 2023	Nov 2, 2023	$0.04	$0.10	+124.1%	✓ BEAT
Q3 2023	Jul 31, 2023	$-0.16	$-0.02	+87.5%	✓ BEAT
Q2 2023	Apr 28, 2023	$-0.25	$-0.16	+36.0%	✓ BEAT
Q1 2023	Mar 1, 2023	$-0.29	$-0.23	+20.7%	✓ BEAT
Q4 2022	Nov 4, 2022	$-0.26	$-0.31	-19.2%	✗ MISS
Q3 2022	Jul 29, 2022	$-0.22	$-0.24	-9.1%	✗ MISS
Q2 2022	May 6, 2022	$-0.21	$-0.10	+52.4%	✓ BEAT
Q1 2022	Feb 25, 2022	$-0.18	$-0.17	+5.6%	✓ BEAT
Q4 2021	Oct 29, 2021	$-0.19	$-0.18	+5.3%	✓ BEAT
Q3 2021	Jul 30, 2021	$-0.18	$-0.15	+16.7%	✓ BEAT
Q2 2021	May 10, 2021	$-0.19	$-0.17	+10.5%	✓ BEAT
Q1 2021	Feb 12, 2021	$-0.08	$0.16	+300.0%	✓ BEAT
Q4 2020	Nov 6, 2020	$-0.20	$-0.13	+35.0%	✓ BEAT
Q3 2020	Jul 31, 2020	$-0.18	$-0.14	+22.2%	✓ BEAT
Q2 2020	May 1, 2020	$-0.15	$-0.17	-13.3%	✗ MISS
Q1 2020	Feb 14, 2020	$-0.05	$0.03	+160.0%	✓ BEAT